Abstracts



WHY SUBMIT TO ISCT 2023?

A Truly Translational Focus on a Global Platform
Whether you focus on basic science and preclinical studies, clinical investigations, manufacturing, regulatory, quality, policy, ethics, or commercialization, your work is vital to advancing the field of cell and gene therapy. ISCT is the place for you to discuss your research with a global community of experts across the translation field.    

Showcase Your Research  - Get Feedback, Collaborate
Be considered for an oral abstract, elevator pitch presentation, or poster presentation and promote your work to global leaders in the cell and gene therapy sector.  Gain exposure to key opinion leaders, potential collaborators, future employers, and expand your professional network.   

Publish Your Work
Accepted abstracts will be published in a special supplement of Cytotherapy, the official journal of ISCT.  With a 2021 Impact Factor of 6.196 and a global readership, Cytotherapy represents an excellent platform to highlight your work to a translational audience. Many studies first presented at ISCT Annual Meetings go on to be published as full-length articles.

Qualify for Awards
ISCT has numerous awards to recognize outstanding abstracts and presentations.  There were 15 abstract award winners at ISCT 2022 and they received a combined total of $15,300 to support their travel to the Annual Meeting. Submit an abstract and join ISCT to qualify!

Publication and Fees

Accepted abstracts will be published in a supplemental version of Cytotherapy, the official journal of ISCT. 
There are no fees associated with submitting an abstract.  Those presenting abstracts will be responsible for their own registration expenses.  


Avoidance of Marketing or Promotion
ISCT requests that presenters avoid the use of trade names and logos for drugs, devices and/or instrumentation in these scientific sessions and to use generic names, where possible. Presentation content will be well-balanced, will be based on generally accepted scientific principles and methods, and will not promote a commercial interest.

Abstract Categories

  • Mesenchymal Stem/Stromal Cells
  • Hematopoietic Stem/Progenitor Cells and Engineering
  • Immunotherapy
  • Exosomes/EVs
  • iPSC
  • Gene Editing/Gene Therapy
  • Tissue Engineering
  • Embryonic, Organ and Other Tissue Specific Stem Cells
  • Process Development and Manufacturing
  • Regulatory Affairs, Quality Systems, Policy and Ethics

Full List of Abstract Categories

Awards

  • Top Scoring Abstract Award ($1500 USD)
  • Best Poster Award ($1500 USD) - Sponsored by BioCanRx
  • Early Stage Professionals Awards ($1000 USD)
    • 3 available
  • Technologist Awards ($1000 USD)
    • 3 available
  • Top Scoring Emerging Economies Abstract Award ($1,000 USD) 
  • Best Elevator Pitch Abstract Award ($1,000 USD)
  • ESP Rookie of the Year Award ($500 USD)

Eligibility Criteria: Individuals must be presenting an abstract at ISCT 2023 and be a current ISCT member

Guidelines and Policies

  • The abstract body cannot exceed 2500 characters, exclusive of the title, author block, images, and tables
  • Note that spaces count as characters
  • Abstracts must be submitted via the online Abstract Submission System. Abstracts will NOT be accepted by email, mail, or fax
  • ISCT may reject abstracts that are considered inappropriate for any reason. Abstracts, once submitted, can only be withdrawn from publication no later than March 6, 2023. If not withdrawn by this deadline, All accepted abstracts will be published in the final program and abstract supplement
  • Abstract presenters MUST be registered for the meeting. For those requiring acceptance notifications before registering, ISCT 2023 will allow up to two weeks after acceptance for these individuals to register
  • Abstracts submitted to the ISCT 2023 Annual Meeting are embargoed from the time of submission.
  • For the abstract to be eligible for presentation at the ISCT 2023 Annual Meeting, information contained within, as well as additional data and information to be presented about the content, may not be published elsewhere or made public before the abstract has been published/presented at the ISCT 2023 Annual Meeting.
  • Authors must notify ISCT if, after the submission deadline, the submitted abstract is accepted for publication elsewhere and will be published before the ISCT 2023 Annual Meeting. Publication before the meeting may result in the abstract being removed from the conference.
  • If the Embargo Policy is violated, the abstract may be withdrawn by ISCT from presentation at the ISCT 2023 Annual Meeting and from publication in the abstract supplement.

*An embargo means that information from any abstract or presentation may not be announced,
publicized, or distributed before the embargo date and time.


Hear from Past ISCT Abstract Awards Winners:

Sabiha Hacibekiroglu‏‏‎, ‎PhD
Research Associate
Lunenfeld-Tanenbaum Research Institute
Toronto, ON, Canada
ISCT 2021 Early Stage Professional Award Winner
"Exposure of my work to an international audiences and premier publications gave me constructive and valuable feedback that will inform further work in our field. Having all the top scholars and researchers together, to collaborate and be inspired by each other, is something that can only be achieved at this scale and with this caliber of participants.

Participation with ISCT gives you the opportunity to present your research and connect with international colleagues, opening up the possibility for new perspectives and collaboration. The Networking and Partnering Platform of ISCT makes for an inclusive and productive atmosphere that has been highly beneficial for my work."




Michelle Cox,‏‏‎ ‎M.S.

Senior Research Technologist
Mayo Clinic
Rochester, MN, USA
ISCT 2021 Technologist Abstract Award Winner
"ISCT meetings represent a unique setting where not only basic science and clinical work are presented but also the process development and business aspects of cell therapy. This is an opportunity to listen to, share your work, and receive feedback from an audience with diverse experience."